Takara Bio (4974 JP): Corona Cliff Set to Jeopardize FY24 Financial; Formulated FY26 Management Plan
Takara Bio is anticipating 32% decline in revenue in FY24. Both operating and net profits are expected to decline 60%+ in FY24. The company aims to...
380 Views
Seegene (096530 KS): Recovery of Non-COVID Sales to Drive Future Growth
Seegene is seeing slow recovery in non-COVID product revenue, with Q2 non-COVID product revenue increasing 21% q/q. At the current level Seegene...
395 Views
New Covid Variant Raises Fear: Stocks to Own to Buck the Trend
Amidst the rising fear for the new Covid variant, investors can focus on molecular diagnostic stocks, as testing demand will be increasing again.
668 Views
Seegene (096530 KS): Worst Seems to Be Over; Non-COVID Revenue to Dictate Long-Term Growth
Seegene is expected to see COVID testing revenue recovery in H2, driven by surging delta variants in Europe and some Asian countries. Non-COVID...
447 Views
Tesla: S&P500 Inclusion Secured?
On 22 July, Tesla Motors (TSLA US) reported a profit for Q2 2020 making it the fourth consecutive quarterly profit. Hitting that milestone makes...
750 Views